Authors
Latest:
Targeted Therapies Showing Promise in Colorectal CancerBenjamin Weinberg, MD, discusses novel agents that may impact the treatment landscape for colorectal cancer once made available in the community setting.
Latest:
Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung CancerIn patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.
Latest:
Obesity as a Risk Factor for Inflammatory Breast CancerBeth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.
Latest:
Similar HRQOL With Gilteritinib vs Placebo in FLT3-ITD+ AML Post-HCTBetty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.
Latest:
Challenges Remain to be Addressed With CAR T-Cell Therapy in DLBCLBianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.
Latest:
<em>RICTOR</em> Amplification in Lung CancerBilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.
Latest:
New Collaboration Forms for Immunotherapy Regimens in Hematologic MalignanciesMedImmune Limited, a subsidiary of AstraZeneca PLC, and Celgene International II Sà rl, a subsidiary of Celgene Corporation, have formed a strategic collaboration for the development and commercialization of AstraZeneca’s anti-programmed cell death-ligand 1 (PD-L1) agent MEDI4736.
Latest:
Patient Adherence, a Challenge of Oral ChemotherapyAdvances in oral chemotherapy are radically changing the way doctors, pharmacists, and their patients manage cancer, yet oral chemotherapy requires the patients themselves to correctly administer the drug, causing issues in patient adherence.<br />
Latest:
Exploring the Role of Genomic Testing in Urothelial CancerBishoy M. Faltas, MD, discusses the current use of genomic testing to guide urothelial cancer treatment.
Latest:
Tumor Tissue Analysis Provides Insight Into Tumor HeterogeneityBishoy M. Faltas, MD, discusses the significance of studying the response of tumor tissue to mutation-targeted agents in urothelial cancer.
Latest:
Gamble Discusses Exciting Topics at the Upcoming 2018 Community Oncology ConferenceRobert "Bo" Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), discusses some of the exciting topics that will be covered during the upcoming 2018 Community Oncology Conference.
Latest:
The Side Effects of Lung Cancer TreatmentBonnie Addario, a lung cancer survivor, discusses toxicities involved during lung cancer treatment.
Latest:
Chemotherapy Safe After Radium-223 for Men With mCRPCThe explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.
Latest:
Microwave Ablation for the Treatment of Liver CancerBoris Kuvshinoff II, MD, MBA, associate professor, Division of Gastrointestinal/Endocrine Surgery, Department of Surgical Oncology, director, Liver and Pancreas Tumor Center, Roswell Park Cancer Institute, discusses microwave ablation therapy for the treatment of liver cancer.
Latest:
Ibrutinib in the Management of B-cell MalignanciesWhile ibrutinib is a relatively new option in the treatment of B-cell NHL, it has convincing antitumor activity as a single agent in a wide variety of B-cell lymphoma subtypes and is a viable therapeutic option for patients.
Latest:
Treating Patients With Indolent Lymphomas in the Relapsed SettingBrad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.
Latest:
Immunotherapy Combinations Improve Survival in Advanced Renal Cell CarcinomaBradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.
Latest:
Ibrutnib in Older Patients With Mantle Cell LymphomaBrad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.
Latest:
KEYNOTE-826: Knowledge Gained for Cervivcal Cancer TreatmentBradley J. Monk, MD, FACS, FACOG, explains the implications of the phase 3 KEYNOTE-826 clinical trial.
Latest:
Behind KEYNOTE-826 in Persistent, Recurrent, or Metastatic Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the rationale behind the KEYNOTE-826 study.
Latest:
Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Latest:
Phase 2 Study Tests Cabo/Nivo/Ipi in RCCvhBradley McGregor, MD, discusses the rationale behind the multi-institutional, prospective, single-arm phase 2 trial of cabozantinib, nivolumab, and ipilimumab for the treatment of patients with renal cell carcinoma with variant histologies.
Latest:
OUTBACK Trial Reveals No Benefit for Adjuvant Chemotherapy in Cervical CancerBradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.
Latest:
Improving Community Oncology Practices Through the American Oncology NetworkThe American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
Latest:
Ibrutinib Maintenance Appears Safe in MCL Following Induction TherapyIbrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.
Latest:
Identification of EGFR Mutations Impacts Overall Prognosis in Lung CancersBrennan J. Decker, MD, PhD, discusses the role of identifying <em>EGFR</em> mutations in patients with lung cancers. In lung adenocarcinoma, there are many different activating mutations that can lead to the development of cancer, Decker explains.
Latest:
Understanding Molecular Subtypes of SarcomaBrian A. Van Tine, MD, PhD, assistant professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses the importance of understanding molecular subtypes of sarcoma.
